O	0	10	Randomized
O	11	16	trial
O	17	22	using
B-intervention	23	35	gonadotropin
I-intervention	35	36	-
I-intervention	36	45	releasing
I-intervention	46	53	hormone
I-intervention	54	61	agonist
I-intervention	62	73	triptorelin
O	74	77	for
O	78	81	the
B-condition	82	94	preservation
I-condition	95	97	of
I-condition	98	105	ovarian
I-condition	106	114	function
O	115	121	during
O	122	123	(
O	123	126	neo
O	126	127	)
O	127	135	adjuvant
O	136	148	chemotherapy
O	149	152	for
O	153	159	breast
O	160	166	cancer
O	166	167	.

O	168	180	Chemotherapy
O	180	181	-
O	181	188	induced
O	189	199	amenorrhea
O	200	202	is
O	203	204	a
O	205	212	serious
O	213	220	concern
O	221	224	for
O	225	230	women
O	231	241	undergoing
O	242	248	cancer
O	249	256	therapy
O	256	257	.

O	258	262	This
O	263	274	prospective
O	275	285	randomized
O	286	291	trial
O	292	301	evaluated
O	302	305	the
O	306	309	use
O	310	312	of
O	313	325	gonadotropin
O	325	326	-
O	326	335	releasing
O	336	343	hormone
O	344	345	(
O	345	349	GnRH
O	349	350	)
O	351	357	analog
O	358	369	triptorelin
O	370	372	to
O	373	381	preserve
O	382	389	ovarian
O	390	398	function
O	399	401	in
O	402	407	women
O	408	415	treated
O	416	420	with
O	421	433	chemotherapy
O	434	437	for
O	438	443	early
O	443	444	-
O	444	449	stage
O	450	456	breast
O	457	463	cancer
O	463	464	.

B-eligibility	465	478	Premenopausal
I-eligibility	479	484	women
I-eligibility	485	488	age
I-eligibility	489	491	44
I-eligibility	492	497	years
I-eligibility	498	500	or
I-eligibility	501	508	younger
O	509	513	were
O	514	522	randomly
O	523	531	assigned
O	532	534	to
O	535	542	receive
O	543	549	either
O	550	561	triptorelin
O	562	564	or
B-control	565	567	no
I-control	568	579	triptorelin
O	580	586	during
O	587	588	(
O	588	591	neo
O	591	592	)
O	592	600	adjuvant
O	601	613	chemotherapy
O	614	617	and
O	618	622	were
O	623	630	further
O	631	641	stratified
O	642	644	by
O	645	648	age
O	649	650	(
O	650	651	<
O	652	654	35
O	654	655	,
O	656	658	35
O	659	661	to
O	662	664	39
O	664	665	,
O	666	667	>
O	668	670	39
O	671	676	years
O	676	677	)
O	677	678	,
O	679	687	estrogen
O	688	696	receptor
O	697	703	status
O	703	704	,
O	705	708	and
O	709	721	chemotherapy
O	722	729	regimen
O	729	730	.

O	731	741	Objectives
O	742	750	included
O	751	754	the
O	755	765	resumption
O	766	768	of
O	769	775	menses
O	776	779	and
O	780	786	serial
O	787	797	monitoring
O	798	800	of
O	801	809	follicle
O	809	810	-
O	810	821	stimulating
O	822	829	hormone
O	830	831	(
O	831	834	FSH
O	834	835	)
O	836	839	and
O	840	847	inhibin
O	848	849	A
O	850	853	and
O	854	855	B
O	856	862	levels
O	862	863	.

O	864	872	Targeted
O	873	876	for
O	877	880	124
O	881	889	patients
O	890	894	with
O	895	896	a
O	897	904	planned
O	905	906	5
O	906	907	-
O	907	911	year
O	912	918	follow
O	918	919	-
O	919	921	up
O	921	922	,
O	923	926	the
O	927	932	trial
O	933	936	was
O	937	944	stopped
O	945	948	for
O	949	957	futility
O	958	963	after
B-total-participants	964	966	49
O	967	975	patients
O	976	980	were
O	981	989	enrolled
O	990	991	(
O	991	997	median
O	998	1001	age
O	1001	1002	,
B-age	1003	1005	39
I-age	1006	1011	years
O	1011	1012	;
O	1013	1018	range
O	1018	1019	,
O	1020	1022	21
O	1023	1025	to
O	1026	1028	43
O	1029	1034	years
O	1034	1035	)
O	1035	1036	;
B-total-participants	1037	1039	47
O	1040	1048	patients
O	1049	1053	were
O	1054	1061	treated
O	1062	1071	according
O	1072	1074	to
O	1075	1083	assigned
O	1084	1090	groups
O	1091	1095	with
O	1096	1100	four
O	1101	1107	cycles
O	1108	1110	of
O	1111	1121	adriamycin
O	1122	1126	plus
O	1127	1143	cyclophosphamide
O	1144	1149	alone
O	1150	1152	or
O	1153	1161	followed
O	1162	1164	by
O	1165	1169	four
O	1170	1176	cycles
O	1177	1179	of
O	1180	1190	paclitaxel
O	1191	1193	or
O	1194	1197	six
O	1198	1204	cycles
O	1205	1207	of
O	1208	1220	fluorouracil
O	1220	1221	,
O	1222	1232	epirubicin
O	1232	1233	,
O	1234	1237	and
O	1238	1254	cyclophosphamide
O	1254	1255	.

B-outcome	1256	1268	Menstruation
I-outcome	1269	1276	resumed
O	1277	1279	in
B-cv-bin-abs	1280	1282	19
O	1283	1284	(
B-cv-bin-percent	1284	1286	90
I-cv-bin-percent	1286	1287	%
O	1287	1288	)
O	1289	1291	of
B-control-participants	1292	1294	21
O	1295	1303	patients
O	1304	1306	in
O	1307	1310	the
O	1311	1318	control
O	1319	1324	group
O	1325	1328	and
O	1329	1331	in
B-iv-bin-abs	1332	1334	23
O	1335	1336	(
B-iv-bin-percent	1336	1338	88
I-iv-bin-percent	1338	1339	%
O	1339	1340	)
O	1341	1343	of
B-intervention-participants	1344	1346	26
O	1347	1349	in
O	1350	1353	the
O	1354	1365	triptorelin
O	1366	1371	group
O	1372	1373	(
O	1373	1374	P
O	1374	1375	=
O	1376	1377	.
O	1377	1379	36
O	1379	1380	)
O	1380	1381	.

B-outcome	1382	1388	Menses
I-outcome	1389	1397	returned
O	1398	1403	after
O	1404	1405	a
O	1406	1412	median
O	1413	1415	of
B-iv-cont-median	1416	1417	5
I-iv-cont-median	1417	1418	.
I-iv-cont-median	1418	1419	8
I-iv-cont-median	1420	1426	months
O	1427	1428	(
O	1428	1433	range
O	1433	1434	,
O	1435	1436	1
O	1437	1439	to
O	1440	1442	19
O	1443	1449	months
O	1449	1450	)
O	1451	1456	after
O	1457	1467	completion
O	1468	1470	of
O	1471	1483	chemotherapy
O	1484	1486	in
O	1487	1490	the
O	1491	1502	triptorelin
O	1503	1509	versus
B-cv-cont-median	1510	1511	5
I-cv-cont-median	1511	1512	.
I-cv-cont-median	1512	1513	0
I-cv-cont-median	1514	1520	months
O	1521	1522	(
O	1522	1527	range
O	1527	1528	,
O	1529	1530	0
O	1531	1533	to
O	1534	1536	28
O	1537	1543	months
O	1543	1544	)
O	1545	1547	in
O	1548	1551	the
O	1552	1559	control
O	1560	1563	arm
O	1564	1565	(
O	1565	1566	P
O	1566	1567	=
O	1568	1569	.
O	1569	1571	58
O	1571	1572	)
O	1572	1573	.

B-cv-bin-abs	1574	1577	Two
O	1578	1586	patients
O	1587	1588	(
O	1588	1591	age
O	1592	1594	26
O	1595	1598	and
O	1599	1601	35
O	1602	1607	years
O	1608	1610	at
O	1611	1617	random
O	1618	1628	assignment
O	1628	1629	)
O	1630	1632	in
O	1633	1636	the
O	1637	1644	control
O	1645	1650	group
O	1651	1654	had
B-outcome	1655	1666	spontaneous
I-outcome	1667	1678	pregnancies
I-outcome	1679	1683	with
I-outcome	1684	1688	term
I-outcome	1689	1699	deliveries
O	1699	1700	.

B-outcome	1701	1704	FSH
I-outcome	1705	1708	and
I-outcome	1709	1716	inhibin
I-outcome	1717	1718	B
I-outcome	1719	1725	levels
O	1726	1736	correlated
O	1737	1741	with
O	1742	1751	menstrual
O	1752	1758	status
O	1758	1759	.

O	1760	1764	When
O	1765	1775	stratified
O	1776	1779	for
O	1780	1783	age
O	1783	1784	,
O	1785	1793	estrogen
O	1794	1802	receptor
O	1803	1809	status
O	1809	1810	,
O	1811	1814	and
O	1815	1824	treatment
O	1825	1832	regimen
O	1832	1833	,
O	1834	1844	amenorrhea
O	1845	1850	rates
O	1851	1853	on
O	1854	1865	triptorelin
O	1866	1870	were
O	1871	1881	comparable
O	1882	1884	to
O	1885	1890	those
O	1891	1895	seen
O	1896	1898	in
O	1899	1902	the
O	1903	1910	control
O	1911	1916	group
O	1916	1917	.
